Phasebio Pharmaceuticals (PHAS) Return on Assets ROA from the second quarter of 2022 to second quarter of 2021 and for the year 2022, Average High and Low, Fundamental Ratios from Jun 30 2022 to Jun 30 2021 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Phasebio Pharmaceuticals Inc.  (NASDAQ: PHAS)


Phasebio Pharmaceuticals's ROA from the second quarter of 2022 to the second quarter of 2021 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Phasebio Pharmaceuticals's ROA in the second quarter of 2022?
Phasebio Pharmaceuticals Inc. recorded a cumulative net loss of $-103 million during 12 months ending in the second quarter of 2022, resulting in a negative return on assets (ROA) of -208.55%.

However, within the Healthcare sector 1111 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2022 from 5467 to 5595.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2022)
II. Quarter		 (Mar 31 2022)
I. Quarter		 (Dec 31 2021)
IV. Quarter		 (Sep 30 2021)
III. Quarter		 (Jun 30 2021)
II. Quarter
Y / Y Total Assets Change -78.09 % -61.71 % 21.55 % 34.97 % 43.47 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -103 -115 -131 -118 -112
Return On Assets (TTM) -208.55 % -166.91 % -155.61 % -145.07 % -145.67 %
PHAS's Total Ranking # 5595 # 5467 # 5806 # 4776 # 4809
Total Assets (TTM) in million 22 38 60 77 100
Seq. Total Assets Change -42.81 % -36.24 % -22.14 % -22.82 % -0.07 %
Seq. Net Income Change - - - - -

PHAS's 5 Years Annual ROA >> Back to PHAS Management Effectiveness >> Compare PHAS ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 548
Sector # 1112
Overall # 5462

Return On Assets Statistics
High Average Low
-27.05 %
-114.88 %
-206.61 %
(Jun 30 2019)   (Jun 30 2022)





Financial Statements
Phasebio Pharmaceuticals's Assets $ 22 million PHAS's Balance sheet
Phasebio Pharmaceuticals's Income $ -17 million Quarterly PHAS's Income Statement
PHAS's Income by Division See PHAS's Income by Division



Annual Return On Assets (Dec 31 2021)
FY 2021		 (Dec 31 2020)
FY 2020		 (Dec 31 2019)
FY 2019		 (Dec 31 2018)
FY 2018
FY
Y / Y Total Assets Change 21.55 % -40.15 % 30.89 % - -
Total Assets in million 60 49 82 63 0
Y / Y Net Income Change - - - - -
Net Income in million -131 -99 -39 -24 0
Annual Return On Assets -218.4 % -199.63 % -47.58 % -37.84 % -

PHAS's 5 Years Annual ROA >> Back to PHAS Management Effectiveness >> Compare PHAS ROA to its Competitors



More Return On Assets Ratios
PHAS's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PHAS's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PHAS's Competitors
Subscribers only: Roa for Phasebio Pharmaceuticals's Suppliers
Subscribers only: Return On Assets for PHAS's Customers

You may also want to know
PHAS's Roi PHAS's Inventory Turnover Ratio PHAS's Growth Rates PHAS's Dividend Comparisons
PHAS's Profitability Ratios PHAS's Asset Turnover Ratio PHAS's Dividend Growth
PHAS's Roe PHAS's Valuation Ratios PHAS's Financial Strength Ratios PHAS's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2022, within Healthcare Sector ROA

Date modified: 2026-09-26T07:35:42+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.